Detalles de la búsqueda
1.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 25(5): 614-625, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38697155
2.
Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend.
BMC Public Health
; 17(1): 283, 2017 03 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28351348
3.
Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
Eur J Health Econ
; 2023 Jul 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37486557
4.
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies.
Target Oncol
; 17(6): 655-663, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36342619
5.
Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019.
Clinicoecon Outcomes Res
; 14: 189-203, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35411162
Resultados
1 -
5
de 5
1
Próxima >
>>